Alpha Mark Advisors, LLC Cytom X Therapeutics, Inc. Transaction History

Alpha Mark Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 19, 2024	BUY	$1.07 - $1.55 $13,519 - $19,584	12,635 Added 119.79%	23,183 $36,000
Q2 2023 Jul 28, 2023	BUY	$1.41 - $1.92 $8,481 - $11,548	6,015 Added 132.69%	10,548 $18,000
Q1 2023 May 04, 2023	BUY	$1.48 - $2.88 $6,708 - $13,055	4,533 New	4,533 $7,000
Q2 2022 Aug 11, 2022	BUY	$1.53 - $2.89 $26,010 - $49,130	17,000 Added 566.67%	20,000 $37,000
Q1 2022 May 02, 2022	BUY	$2.67 - $4.68 $8,010 - $14,040	3,000 New	3,000 $8,000
Q3 2020 Nov 06, 2020	SELL	$6.55 - $8.83 $9,104 - $12,273	-1,390 Closed	0 $0
Q1 2020 Apr 24, 2020	BUY	$3.61 - $8.6 $1,490 - $3,551	413 Added 42.27%	1,390 $11,000
Q4 2019 Feb 07, 2020	BUY	$5.17 - $8.91 $2,274 - $3,920	440 Added 81.94%	977 $8,000
Q3 2019 Nov 01, 2019	BUY	$7.38 - $12.25 $1,291 - $2,143	175 Added 48.34%	537 $4,000
Q4 2018 Feb 06, 2019	BUY	$12.69 - $18.61 $4,593 - $6,736	362 New	362 $5,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Mark Advisors, LLC with notifications on news.